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The carbohydrate antigen 19-9 (CA 19-9), a determinant
(sialylated lacto-N-fucopentaose 119) of a circulating
oligosaccharide antigen, is a frequently used tumor
marker. Echinococcus spp. infects humans throughout
the world and may be able to synthesize closely related
molecules which could interfere with the measurement
and interpretation of CA 19-9 concentration. The main
objective of the present study was to determine the
range of CA 19-9 levels in the sera of patients infected by
E. granulosus (cystic hydatide disease; CYSHD) or E.
multilocularis (alveolar hydatide disease; ALVHD).
Serum samples were collected from patients (aged
10–85 years) over a period of 5 years: from 19 patients
with CYSHD and from 20 patients with ALVHD. Infec-
tion was confirmed by positive Echinococcus serology
and clinical evidence provided by imaging and/or
histopathological findings.
CA 19-9 was detectable in 13 patients with CYSHD
(13.5 ± 8.5 kU/l) and 13 patients with ALVHD (30.0 ± 21
kU/l; p < 0.05). Thus ALVHD patients exhibited a signif-
icantly higher plasma level of CA 19-9 than CYSHD pa-
tients. The serum level of CA 19-9 assessed with an in-
creased cut-off value (> 22 kU/l) was elevated in nine
(45%) of 20 ALVHD patients compared to two (11%) of
19 CYSHD patients (p < 0.05).
Sera from patients with Echinococcus multilocularis
infection contain substances which cross-react with
CA 19-9. These substances originate either from the
parasite or are synthesized by the host in response to
the infection, and possibly bear the Lewis-a antigen or
closely related structures which are recognized by
anti-CA 19-9 antibodies. Our findings are relevant to
the investigation of patients presenting with cystic le-
sions for which the differential diagnosis includes an
infectious or neoplastic origin.
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multilocularis specific carbohydrate antigen; II/3-10 anti-
gen, recombinant Echinococcus multilocularis antigen;
spp, species.
Introduction
Echinococcus spp. infections in humans occur
throughout the world (1). Cystic hydatide disease
(CYSHD) is caused by E. granulosus. The liver is the
most frequent site of hydatid cyst localization (> 65%),
followed by the lungs, spleen, kidneys, heart, bone
and, rarely, the central nervous system. Alveolar hy-
datide disease (ALVHD) is caused by E. multilocularis,
and the primary localization in humans is again the
liver (> 95%) (2). Hence a systemic infection with E.
granulosus or E. multilocularis can mimic a metastatic
cancer and should be taken into consideration as a dif-
ferential diagnosis in malignant disease. As progres-
sive ALVHD is one of the most lethal helminthic dis-
eases in humans, early diagnosis of infection may
considerably improve prognosis due to the potential
for radical surgery. Only complete surgical removal of
the entire parasite lesion offers prospects for curative
treatment of the active infection (3). For patients with-
out radical surgery, the mortality rate was found to be
92% within 10 years after primary diagnosis (4).
Carbohydrate antigen 19-9 (CA 19-9) is the carbohy-
drate determinant (sialylated lacto-N-fucopentaose
119) of a circulating oligosaccharide antigen which was
detected originally, using a monoclonal antibody, in
human colon carcinoma growing in cell culture. Raised
serum values of the antigen have been found on glyco-
proteins in the sera of patients with colorectal, gastric,
and pancreatic cancers (5). The normal range of 
CA 19-9 in serum of healthy subjects has been estab-
lished in different studies, and generally a CA 19-9 level
above 37 kU/l was found in less than 2% of the tested
individuals (6–8).
The main objective of the present study was to de-
termine the range of CA 19-9 concentrations in CYSHD
and ALVHD patients. The idea stemmed from the pre-
sent lack of data on CA 19-9 values in serum of such pa-
tients. The antigen may show serological cross-reactiv-
ity in that the parasite has been reported to synthesize
closely related molecules (9–11). Such molecules may
also potentially confuse with the oncological/prognos-
tic interpretation of CA 19-9.
Patients and Methods
Serum samples were obtained from 19 patients with CYSHD
and from 20 patients with ALVHD (20 females/19 males; me-
dian (SD) age 44 ± 20 years, range: 10 to 85 years). Infection
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was confirmed by positive Echinococcus serology comple-
menting clinical evidence provided by imaging and/or
histopathological findings. Sera were collected over a period
of 5 years and kept frozen at –80 °C until use. In line with a pre-
vious study (12) documenting the diagnostic characteristics of
the enzyme-linked immunosorbent assay (ELISA), sera were
immunodiagnostically investigated using the E. granulosus
hydatide fluid (EgHF-)antigen and the E. multilocularis carbo-
hydrate (Em2) and the recombinant II/3-10 antigen. The test
procedures were exactly as published earlier (12).
Samples from 19 patients with CYSHD and from 20 patients
with ALVHD were thawed, mixed and centrifuged at 2000 ´ g
for 10 min prior to testing. CA 19-9 was determined using
the automatic Boehringer Enzymun-Test® system ES300
(Boehringer Mannheim Diagnostics, Tutzing, Germany), ac-
cording to the manufacturer’s instructions. This ELISA is based
on the 1116NS-119 antibody from Centocor (13). It uses strep-
tavidin-coated tubes with a biotinylated first antibody and a
peroxydase-labeled second antibody. The widely used cut-off
concentration based on healthy subjects is 22.0 kU/l (95th per-
centile = 21.5 kU/l) (13, 14). In earlier studies, as mentioned
above, the cut-off was set at 37 kU/l (99th percentile = 37 kU/l).
Other manufacturers may indicate different reference
ranges for CA 19-9, based either on the 99% distribution of the
values in healthy subjects, or on cut-off values related to the
diagnostic sensitivity for tumor detection. No cross-reactions
between the antibodies used in the test and other antigens
than CA 19-9 have been reported so far.
The statistics software package SYSTAT was used for data
analysis (SYSTAT 6.01, Inc., Evanston, USA). Data are ex-
pressed as mean values ± standard deviation (SD) Pearson
Chi-square test (2 ´ 2 tables) and analysis of variance
(ANOVA), including Tukey post hoc test, were applied as ap-
propriate.
Results
The baseline immunodiagnostic results confirming
Echinococcosis are documented in Table 1. ELISA for
EgHF was positive in 18 (95%) of 19 patients with
CYSHD and in 19 (95%) of 20 patients with ALVHD, re-
spectively. The E. multilocularis-specific Em2 and II/3-
10 tests provided positive reactions in 16 and 8 cases
respectively. When combining the results of both anti-
gens, 19 (95%) of the sera were positive in at least one
of the tests.
The mean (SD) serum CA 19-9 level for all patients was
14.5 ± 18 kU/l. In patients with measurable levels of CA
19-9 (³ 0.05 kU/l), serum values ranged from 5.1 kU/l to
74.2 kU/l. The distribution of CA 19-9 serum concentra-
tions in CYSHD and ALVHD patients is shown in Figure 1.
Fig. 1 Range and distribution of CA 19-9 serum concentra-
tions in 19 patients with cystic hydatide disease (shaded bars)
and in 20 patients with alveolar hydatide disease (black bars).
Patients with Patients with
CYSHD (n = 19) ALVHD (n = 20) p-Value
Age (years; median, range) 31 (10 to 80) 49 (32 to 85) < 0.05
Female/male (n) 9/10 11/9 ns
Patients with CA 19-9 < 0.05 kU/l (n, %) 6 (32) 7 (35) ns
Patients with CA 19-9 0.05–22 kU/l (n, %) 11 (58) 4 (20) ns
Patients with CA 19-9 > 22 kU/l (n, %) 2 (11) 9 (45) < 0.05
CA 19-9 (kU/l) in patients with detectable 13.5 ± 8.5 30.0 ± 21 < 0.05
CA 19-9 (>0.05 kU/l), (mean ± SD)
EgHF-ELISA (AU; mean ± SD) 69.0 ± 36 71.2 ± 34 ns
Patients with positive EgHF-ELISA (n, %) 18 (95) 19 (95) ns
Patients with positive Em2-ELISA (n, %) 3 (16) 16 (80) < 0.01
Patients with positive II/3-10-ELISA (n, %) 0 (0) 8 (40) < 0.001
EgHF-ELISA: enzyme-linked immunosorbent assay (ELISA)
for the E. granulosus hydatide fluid EgHF-antigen; Em2-
ELISA: ELISA for the E. multilocularis carbohydrate Em2; II/3-
10-ELISA: ELISA for the recombinant II/3-10 antigen. AU de-
notes antibody units. The carbohydrate antigen 19-9 (CA 19-9)
was determined by using the automatic Boehringer Enzymun-
Test® system ES300 based on the 1116NS-199 antibody from
Centocor. ns: not significant.
Tab. 1 Clinical and laboratory characteristics of patients with
Echinococcus granulosus (cystic hydatide disease; CYSHD) or
Echinococcus multilocularis (alveolar hydatide disease;
ALVHD) infection.
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There was no correlation between serum values of
CA 19.9 (kU/l) and the amount of antibody units (AU) of
EgHF, Em2 and the recombinant antigen II/3-10. There
was also no correlation with age of the patients
CA 19-9 was detectable in 13 patients with CYSHD
and in 13 patients with ALVHD (Table 1). ALVHD pa-
tients exhibited higher serum levels of CA 19-9 than
CYSHD patients (13.5 ± 8.5 kU/l vs. 30.0 ± 21 kU/l, p <
0.05). The serum level of CA 19-9 assessed with higher
cut-off value (> 22 kU/l) was elevated in 9 (45%) out of
20 ALVHD patients compared to 2 (11%) out of 19
CYSHD patients (p < 0.05).
Discussion
The concentration of the tumor marker CA 19-9 was in-
creased in 13 (28%) of 39 sera from patients with
CYSHD or ALVHD when assessed with a cut-off value
based on healthy subjects (95th percentile: 22 kU/l) (6,
13, 14). Del Villano et al. (6) showed that 99.6% of
healthy blood donors have values below 37 kU/l. How-
ever, for clinical screening purposes a cut-off value of
22 kU/l is commonly used, as opposed to the cut-off
value of 37 kU/l (99th percentile).
The observation of increased CA 19-9 concentrations
in patients with an Echinococcus infection is in line
with previous reports of elevated serum CA 19-9 con-
centrations in patients with benign liver disease, in-
cluding infectious diseases affecting the liver, such as
viral hepatitis (15, 16). One of the main findings of our
study was that the tumor marker CA 19-9 appeared
more frequently, and was markedly elevated in sera
from ALVHD patients as compared to CYSHD patients
(45% vs. 11%). A putative explanation for this could be
provided by differences in the cellular and humoral im-
mune responses to CYSHD and ALVHD (17–19). In
ALVHD, the larval stage of E. multilocularis leads to an
active and tumor-like proliferation of the primary infec-
tion in the liver. Conversely, ALVHD is not associated
with containment of the lesions by reactive fibrosis.
The involvement of cellular immunity in ALVHD leads
to an intense granulomatous infiltration observed
around the hepatic parasitic lesions (17, 18). A further
emphasis on the tumor-like growth and behavior or E.
multilocularis metacestode was given by the recent
identification and characterization of the 14-3-3 protein
overexpressed at the metacestode stage of the parasite
(20). The 14-3-3 proteins seem to act as key molecules
in the processes of cell differentiation and proliferation,
and have also been directly implicated in abnormal cell
proliferation phenomena (21, 22).
A large proportion of patients with ALVHD responds
with a marked synthesis of parasite-specific antibod-
ies, including all isotypes of immunoglobulins. How-
ever, humoral and cell-mediated immune responses
are different in susceptible vs. resistant individuals
(23). Since the course of cellular and humoral immune
response is different in cured patients who had re-
ceived radical surgery, compared to patients with only
a partial surgery or no resection, we could postulate
that the regulation of antigen synthesis, including ‘‘tu-
mor-related’’ antigens such as the oligosaccharide CA
19-9, may also depend on the clinical course as well
as on its relationship to surgical interventions and
chemotherapy. This is underscored by our study where
we included an additional follow-up of a 49-year-old
male patient with hepatic CYSHD. This allowed us to
study the time course of CA 19-9 serum concentrations
after surgical removal of the parasitic lesion in the liver.
We observed, subsequent to the radical resection of
the hepatic cyst, a parallel decrease in CA 19-9 serum
concentration and in EgHF-ELISA antibody level as
compared to the preoperative values (5.8 kU/l vs. 24.4
kU/l and 0.0 AU vs. 70 AU, respectively).
The epitope recognised by anti-CA 19-9 antibodies is
the sialylated Lewis-a antigen (24), sialylated lacto-N-
fucopentaose II. The Lewis-a antigen ends with a char-
acteristic carbohydrate sequence (Gal b 1–3 [Fuc a 1–4]
Nac.). A glycosphingolipid with a very similar terminal
residue has been found in metacestodes of E. multiloc-
ularis (Gal b 1–6 [Fuc a 1–4] Gal.) (9), and other sialy-
lated fucose-containing glycans were found in hydatid
cyst membranes of E. granulosus (25).
Therefore, we postulate that the blood from pa-
tients with an Echinococcus infection may contain
substances originating from the parasite which have
been sialylated either by the host or by the parasite’s
metabolism. These substances may bear the Lewis-a
antigen or closely related structures which are recog-
nised by anti-CA 19-9 antibodies. Furthermore, it is
conceivable that a subgroup of patients with ALVHD
are able to produce an oligosaccharide similar to the
CA 19-9 antigen, or to induce its synthesis by intra-
hepatic stimulation caused by the inflammation re-
sulting from the E. multilocularis metacestode. The
variability in the production of ‘‘tumor-related’’ anti-
gens in different ALVHD patients could depend on
their immunogenetic background. Putatively, other ex-
ogenous factors such as anthelmintic or surgical treat-
ment may also be involved. These hypotheses need
further investigation.
In conclusion, alveolar hydatide disease (E. multiloc-
ularis) in humans is usually a fatal disease when not di-
agnosed early enough to provide curative treatment
such as radical surgery. Since 45% of the sera from pa-
tients with ALVHD demonstrate elevated CA 19-9 lev-
els, we emphasize the need to consider an infection
with E. multilocularis in patients with cystic lesions in
the liver and/or in other organs, even if the tumor
marker CA 19-9 ist elevated.
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